AnaptysBio Board Member's Planned Stock Sale Follows RSU Vesting

Rhea-AI Filing Summary

Director Dennis M. Fenton of AnaptysBio reported a significant insider transaction on June 18, 2025. The filing details:

• Sale of 3,015 shares of Common Stock at $23.97 per share
• Transaction was executed under a Rule 10b5-1 trading plan established on March 22, 2024
• The sale was primarily to satisfy tax obligations related to restricted stock unit vesting on June 15, 2025
• Following the transaction, Fenton retains direct ownership of 4,965 shares

This transaction appears to be a planned sale for tax purposes rather than a discretionary trade, as evidenced by the pre-established 10b5-1 plan. The sale represents a partial liquidation of Fenton's holdings, maintaining a significant ownership position in the company.

Insider Trade Summary

Net Seller: 3,015 shares ($72,270)

Net Sell 1 txn

Insider FENTON DENNIS M

Role Director

Sold 3,015 shs ($72K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,015	$23.97	$72K

Holdings After Transaction: Common Stock — 4,965 shares (Direct)

Footnotes (1)

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. Shares sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units on June 15, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FENTON DENNIS M

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		S(1)		3,015(2)	D	$23.97	4,965	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024.

2. Shares sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units on June 15, 2025.

	/s/ Eric Loumeau, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of ANAB stock did Dennis Fenton sell on June 18, 2025?

Dennis Fenton sold 3,015 shares of ANAB common stock on June 18, 2025 at a price of $23.97 per share. The sale was made to satisfy a portion of tax obligations related to the vesting of restricted stock units.

How many ANAB shares does Dennis Fenton own after the June 18, 2025 transaction?

Following the reported transaction, Dennis Fenton directly owns 4,965 shares of AnaptysBio (ANAB) common stock.

Was ANAB insider Dennis Fenton's stock sale planned in advance?

Yes, the sale was executed pursuant to a Rule 10b5-1 trading plan that Dennis Fenton adopted on March 22, 2024. This indicates it was a pre-planned transaction rather than a spontaneous sale.

What is Dennis Fenton's role at ANAB?

Dennis Fenton serves as a Director on AnaptysBio's Board of Directors, as indicated by the 'X' marked in the Director box on the Form 4 filing.

Why did ANAB director Dennis Fenton sell shares in June 2025?

The shares were sold specifically to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units that occurred on June 15, 2025, as disclosed in the filing's explanatory notes.